Acute Myocarditis & Inflammatory Cardiomyopathies
Comprehensive emergency evaluation and protocolized management of acute myocarditis and inflammatory cardiomyopathies: distinguishing fulminant myocarditis from acute coronary syndromes (MINOCA: myocardial infarction with non-obstructive coronary arteries); viral etiologies (Coxsackievirus B, Parvovirus B19, SARS-CoV-2); lethal non-viral phenotypes including Giant Cell Myocarditis and Immune Checkpoint Inhibitor (ICI) myocarditis; diagnostic hallmarks on ECG, cardiac biomarkers, POCUS echocardiography, and cardiac MRI; emergent mechanical circulatory support (VA-ECMO, Impella); and high-dose corticosteroid rescue protocols.
Resuscitation Quick Actions • First 2 Minutes
Fulminant Myocarditis Shock
Cardiogenic shock + fever/viral prodrome in young patient: early consultation for VA-ECMO or Impella before multiorgan failure ensues
Immune Checkpoint Inhibitor (ICI)
Any patient on PD-1/PD-L1/CTLA-4 inhibitors with elevated troponin, conduction block, or dysrhythmias -> Stat Methylprednisolone 1 g IV daily
STEMI Mimic Warning
Concave ST elevations with PR depressions and troponin elevation in young patient without CAD risk factors -> Perform emergent angiography to rule out coronary occlusion
Inotrope Selection
Milrinone (0.375-0.75 mcg/kg/min) or Dobutamine (2.5-10 mcg/kg/min) for inotropic support; add Norepinephrine for vasodilation/hypotension
Endomyocardial Biopsy (EMB)
Indicated for acute heart failure of < 2 weeks duration with hemodynamic compromise, or new heart failure with Mobitz II/3rd degree AV block or VT
Dysrhythmia Suppression
Amiodarone is first-line for refractory ventricular tachycardia; avoid Class IC antiarrhythmics and Digoxin (extreme sensitivity and dysrhythmias in myocarditis)
Bottom-Line Clinical Pearl
Acute myocarditis can present as an exact clinical mimic of an acute ST-elevation myocardial infarction (STEMI) or new-onset dilated cardiomyopathy, presenting with profound troponin elevation, cardiogenic shock, and ventricular dysrhythmias in the setting of angiographically normal coronary arteries. In patients presenting with acute cardiogenic shock following a viral prodrome, or patients on cancer immunotherapy (PD-1/CTLA-4 checkpoint inhibitors), suspect fulminant myocarditis immediately. Giant cell and checkpoint inhibitor myocarditis carry mortality rates exceeding 50% without emergent pulse-dose corticosteroids (Methylprednisolone 1 g IV daily) and urgent mechanical circulatory support (VA-ECMO).
Myocarditis represents inflammation of the myocardium characterized by myocyte necrosis and degeneration not caused by ischemic coronary disease. Pathophysiology involves two distinct phases: an initial phase of direct pathogen-mediated myocyte lysis, followed by an immune-mediated phase driven by molecular mimicry, autoreactive T-lymphocytes, and cytotoxic cytokine cascades.
| Etiological Category | Specific Pathogens/Triggers | Clinical Hallmark & Course |
|---|---|---|
| Viral Myocarditis (Most Common) | Coxsackievirus B, Enterovirus, Parvovirus B19, HHV-6, Adenovirus, SARS-CoV-2, Influenza, HIV. | Preceded by viral prodrome (fever, myalgias, pharyngitis, gastroenteritis) 1-2 weeks prior. Ranges from mild chest pain to fulminant cardiogenic collapse. |
| Giant Cell Myocarditis (GCM) | Idiopathic autoimmune T-cell mediated destruction with multinucleated giant cells and extensive eosinophilic infiltration. | Rapidly progressive cardiogenic shock, intractable ventricular tachycardia, and complete heart block in young, previously healthy adults. 70% mortality without emergent immunosuppression or cardiac transplantation. |
| Immune Checkpoint Inhibitor (ICI) Myocarditis | Immunotherapy for oncology: Nivolumab, Pembrolizumab, Ipilimumab (anti-PD-1, anti-PD-L1, anti-CTLA-4). | Onset typically within 1 to 3 months of starting therapy. Often co-occurs with myasthenia gravis or myositis; extremely high case-fatality rate (40-50%) from fatal conduction block and arrest. |
| Eosinophilic/Hypersensitivity | Drug hypersensitivity (sulfonamides, penicillins, anticonvulsants, clozapine) or hypereosinophilic syndrome. | Peripheral eosinophilia, rash, fever, and acute biventricular failure. Reversible upon immediate drug withdrawal and systemic corticosteroids. |
| Diagnostic Modality | Characteristic Myocarditis Findings | Emergency Interpretation & Nuance |
|---|---|---|
| Electrocardiogram (ECG) | Sinus tachycardia out of proportion to fever; diffuse non-specific ST-segment and T-wave changes; diffuse concave ST-elevations mimicking acute pericarditis; pathological Q-waves; or new intraventricular conduction delay (wide QRS > 120 ms). | Presence of new bundle branch block, high-degree AV block, or frequent PVCs/VT portends fulminant disease with imminent cardiovascular collapse. |
| Cardiac Biomarkers | Markedly elevated Cardiac Troponin (I or T) and NT-proBNP/BNP. Troponin levels often remain elevated for weeks (unlike the rapid rise and fall in acute MI). | Elevated troponin + elevated ESR/CRP in a young patient with acute chest pain strongly suggests myopericarditis. (Normal troponin does NOT fully exclude mild myocarditis). |
| Point-of-Care Ultrasound (POCUS) | Global biventricular hypokinesis, reduced ejection fraction, increased left ventricular wall thickness (due to acute interstitial myocardial edema), and small pericardial effusion. | Absence of segmental wall motion abnormalities conforming to a single coronary vascular territory supports myocarditis over acute myocardial infarction. |
| Coronary Angiography | Completely normal coronary arteries without obstructive plaque, ulceration, or thrombus. | Mandatory in patients presenting with STEMI-like changes or cardiogenic shock to exclude acute coronary occlusion before confirming myocarditis. |
Fulminant myocarditis is characterized by sudden, catastrophic hemodynamic collapse requiring inotropic support or mechanical circulatory assist devices within days of symptom onset. Paradoxically, if patients with fulminant viral myocarditis survive the acute inflammatory storm with mechanical circulatory support, their long-term ventricular functional recovery is significantly higher (> 80%) than in chronic indolent myocarditis.
| Clinical Phase/Intervention | Protocol & Pharmacotherapy | Hemodynamic Target & Device Strategy |
|---|---|---|
| Inotropic & Vasopressor Support | - Norepinephrine (0.05–0.5 mcg/kg/min) to maintain MAP >= 65 mmHg. - Milrinone (0.375–0.75 mcg/kg/min; PDE-3 inhibitor, preferred if pulmonary hypertension is present) OR - Dobutamine (2.5–10 mcg/kg/min; beta-1 inotrope). | Avoid high-dose pure alpha-1 agonists (Phenylephrine) which dramatically increase left ventricular afterload and worsen forward failure. Avoid Digoxin due to heightened risk of fatal arrhythmias in inflamed myocardium. |
| Temporary Mechanical Circulatory Support (MCS) | 1. Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO): Provides complete biventricular and respiratory support. 2. Microaxial Left Ventricular Assist Device (Impella): Unloads the left ventricle, reduces LV wall stress, and decreases myocardial oxygen demand. | Early institution of 'ECPELLA' (VA-ECMO combined with Impella for LV venting) before multiorgan end-organ failure and severe lactic acidosis develop. Serves as a bridge to recovery, bridge to durable LVAD, or bridge to urgent heart transplant. |
| Ventricular Dysrhythmia Suppression | - Amiodarone (150 mg IV bolus over 10 min, then 1 mg/min for 6 hours, then 0.5 mg/min) for recurrent VT/VF. - Correct hypokalemia (target K > 4.5 mEq/L) and hypomagnesemia (target Mg > 2.5 mg/dL). | Temporary transvenous cardiac pacing for complete AV block or symptomatic bradycardia. |
| Clinical Condition | Immediate Pharmacological Protocol | Monitoring & Secondary Regimens |
|---|---|---|
| Immune Checkpoint Inhibitor (ICI) Myocarditis | 1. Discontinue all checkpoint inhibitor agents immediately. 2. Methylprednisolone 1,000 mg IV daily for 3 consecutive days, followed by oral Prednisone 1 mg/kg/day with slow taper over 4-6 weeks. | If troponin does not decline by > 50% within 48-72 hours or hemodynamic instability persists: initiate secondary immunosuppression with Abatacept (CTLA-4 agonist: 500-1,000 mg IV), Infliximab (TNF-alpha inhibitor), or Mycophenolate Mofetil. |
| Giant Cell Myocarditis (GCM) | Dual/Triple Immunosuppressive Therapy: 1. Methylprednisolone 1,000 mg IV daily PLUS 2. Cyclosporine (or Tacrolimus) titrated to therapeutic trough levels PLUS 3. Antithymocyte Globulin (ATG) or Muromonab. | Stat Transfer to a tertiary heart transplant center. Up to 50% of GCM patients require orthotopic cardiac transplantation despite maximal medical therapy. |
The STEMI Cath Lab Trap & The Checkpoint Inhibitor Lethality
In young patients presenting with acute retrosternal chest pain, diffuse concave ST elevations, and elevated troponin following a viral infection, emergency clinicians frequently activate the cardiac catheterization laboratory for a presumed STEMI. While coronary angiography is appropriate to exclude acute thrombotic occlusion, never assume clean coronaries means the patient is safe for discharge! Patients with fulminant myocarditis can decompensate from stable sinus rhythm into refractory ventricular fibrillation, third-degree heart block, or cardiogenic shock within hours. All patients with suspected acute myocarditis require admission to an intensive care or telemetry bed. Furthermore, in any cancer patient on immune checkpoint inhibitors (e.g., Nivolumab, Pembrolizumab) presenting with even subtle dyspnea, fatigue, or mild troponin elevation, suspect ICI Myocarditis: mortality approaches 50% from sudden conduction block. Immediately administer high-dose pulse steroids (Methylprednisolone 1 g IV) without waiting for endomyocardial biopsy or cardiac MRI.
Test Your Acute Myocarditis & Inflammatory Cardiomyopathies Clinical Acumen
Directly launch an active-recall practice block from our 8,400+ validated COMLEX Level 1, 2-CE & 3 board question bank with complete explanations.
Related Emergency Protocols & Differentials
Acute Heart Failure & Cardiogenic Shock
Inotropes, vasopressors, and mechanical circulatory support.
Open Protocol Related EM ProtocolAcute Coronary Syndromes & STEMI Equivalents
Coronary occlusion, STEMI equivalents, and cath lab activation.
Open Protocol Related EM ProtocolPericardial Disease, Tamponade & Pericardiocentesis
Pericarditis, cardiac tamponade, and POCUS.
Open Protocol